Matthew Cockerill, BioMed Central's boss, though, points out that Episciences's publishing model may have its drawbacks.

但是，斯林普格生物医学中心的老板马修-科克尔指出，“科学至上”期刊的出版模式可能也有不足之处。

The number of submissions to journals is outpacing reviewers' capacity to deal with them, says Mr Cockerill.Mr Pattinson agrees.

柯克里尔先生说道，现在期刊投稿量使评审员负荷过大。帕丁森先生也承认这一点。

Genome Biology, BMC's flagship journal, which accepts just one paper in ten, passes 40% of the sound but humdrum sort it spurns to its less prestigious sister publications with reviews attached, says Matthew Cockerill, the group's managing director.

BMC(生物医学期刊出版中心)的重点期刊《基因生物学》，文章接收率只有10%，该期刊 40%的比较不错但却单调的被拒文章会转投给比它名气稍小的子期刊，这些文章都附有评审报告，出版中心的总经理马修•柯克里尔说到。